The role of genotypic heterogeneity in wild type virus populations on the selection of nonnucleoside reverse transcriptase inhibitor-resistant viruses

被引:7
作者
Kinjerski, TL [1 ]
Buckheit, RW [1 ]
机构
[1] FREDERICK RES CTR,SO RES INST,VIROL RES GRP,FREDERICK,MD 21701
关键词
HIV-1; reverse transcriptase inhibitors; resistance;
D O I
10.1016/S0166-3542(96)01008-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Virus populations were selected in cell culture using two widely used protocols in order to evaluate the role of selection methodology on the genotype and phenotype of nonnucleoside reverse transcriptase inhibitor resistant viruses. Selection was performed by serial passage of virus in the presence of gradually increasing concentrations of antiviral compound or passage in the presence of a constant high concentration of compound. Using the CEM-SS cell line, the IIIB strain of HIV-1, and identical nonnucleoside reverse transcriptase inhibitors, resistant viruses were obtained and their phenotypic and genotypic properties were defined. Resistant virus populations containing the Y181C amino acid change in the reverse transcriptase were predominantly selected with each of the tested compounds. Several of the compounds selected secondary amino acid changes using both methods. A comparison of the resistant viruses selected in our laboratory using each of the two protocols with viruses reported by a second laboratory employing one of the two methods suggests that genotypic differences in the selected virus isolates may most likely result from Variation in the genetic composition of the respective wild type virus pools, rather than the specific selection methodology employed. These results imply that HIV may select a wide variety of amino acid changes to avoid the inhibitory effects of the nonnucleoside reverse transcriptase inhibitors and the selection of compounds for clinical use in combination with agents possessing non-overlapping resistance phenotypes will require evaluation of the agents against virus isolates possessing each of the mutations known to confer drug resistance. Copyright (C) 1997 Elsevier Science B.V.
引用
收藏
页码:109 / 115
页数:7
相关论文
共 36 条
[1]   OXATHIIN CARBOXANILIDE, A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS REPRODUCTION [J].
BADER, JP ;
MCMAHON, JB ;
SCHULTZ, RJ ;
NARAYANAN, VL ;
PIERCE, JB ;
HARRISON, WA ;
WEISLOW, OS ;
MIDELFORT, CF ;
STINSON, SF ;
BOYD, MR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (15) :6740-6744
[2]   HUMAN-IMMUNODEFICIENCY-VIRUS-1 (HIV-1)-SPECIFIC REVERSE-TRANSCRIPTASE (RT) INHIBITORS MAY SUPPRESS THE REPLICATION OF SPECIFIC DRUG-RESISTANT (E138K)RT HIV-1 MUTANTS OR SELECT FOR HIGHLY RESISTANT (Y181C-]C181I)RT HIV-1 MUTANTS [J].
BALZARINI, J ;
KARLSSON, A ;
SARDANA, VV ;
EMINI, EA ;
CAMARASA, MJ ;
DECLERCQ, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) :6599-6603
[3]   SUPPRESSION OF THE BREAKTHROUGH OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) IN CELL-CULTURE BY THIOCARBOXANILIDE DERIVATIVES WHEN USED INDIVIDUALLY OR IN COMBINATION WITH OTHER HIV-1 SPECIFIC INHIBITORS (IE, TSAO DERIVATIVES) [J].
BALZARINI, J ;
PEREZPEREZ, MJ ;
VELAZQUEZ, S ;
SANFELIX, A ;
CAMARASA, MJ ;
DECLERCQ, E ;
KARLSSON, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) :5470-5474
[4]   KNOCKING-OUT CONCENTRATIONS OF HIV-1-SPECIFIC INHIBITORS COMPLETELY SUPPRESS HIV-1 INFECTION AND PREVENT THE EMERGENCE OF DRUG-RESISTANT VIRUS [J].
BALZARINI, J ;
KARLSSON, A ;
PEREZPEREZ, MJ ;
CAMARASA, MJ ;
DECLERCQ, E .
VIROLOGY, 1993, 196 (02) :576-585
[5]  
BALZARINI J, 1993, MOL PHARMACOL, V44, P694
[6]   OXATHIIN CARBOXANILIDE DERIVATIVES - A CLASS OF NONNUCLEOSIDE HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITORS (NNRTIS) THAT ARE ACTIVE AGAINST MUTANT HIV-1 STRAINS RESISTANT TO OTHER NNRTIS [J].
BALZARINI, J ;
JONCKHEERE, H ;
HARRISON, WA ;
DAO, DC ;
ANNE, J ;
DECLERCQ, E ;
KARLSSON, A .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1995, 6 (03) :169-178
[7]   STRUCTURE-ACTIVITY AND CROSS-RESISTANCE EVALUATIONS OF A SERIES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-SPECIFIC COMPOUNDS RELATED TO OXATHIIN CARBOXANILIDE [J].
BUCKHEIT, RW ;
KINJERSKI, TL ;
FLIAKASBOLTZ, V ;
RUSSELL, JD ;
STUP, TL ;
PALLANSCH, LA ;
BROUWER, WG ;
DAO, DC ;
HARRISON, WA ;
SCHULTZ, RJ ;
BADER, JP ;
YANG, SS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (12) :2718-2727
[8]   RESISTANCE TO 1-[(2-HYDROXYETHOXY)METHYL]-6-(PHENYLTHIO)THYMINE DERIVATIVES IS GENERATED BY MUTATIONS AT MULTIPLE SITES IN THE HIV-1 REVERSE-TRANSCRIPTASE [J].
BUCKHEIT, RW ;
FLIAKASBOLTZ, V ;
YEAGYBARGO, S ;
WEISLOW, O ;
MAYERS, DL ;
BOYER, PL ;
HUGHES, SH ;
PAN, BC ;
CHU, SH ;
BADER, JP .
VIROLOGY, 1995, 210 (01) :186-193
[9]   COMPARITIVE ANTI-HIV EVALUATION OF DIVERSE HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITOR-RESISTANT VIRUS ISOLATES DEMONSTRATES THE EXISTENCE OF DISTINCT PHENOTYPIC SUBGROUPS [J].
BUCKHEIT, RW ;
FLIAKASBOLTZ, V ;
DECKER, WD ;
ROBERSON, JL ;
STUP, TL ;
PYLE, CA ;
WHITE, EL ;
MCMAHON, JB ;
CURRENS, MJ ;
BOYD, MR ;
BADER, JP .
ANTIVIRAL RESEARCH, 1995, 26 (02) :117-132
[10]   BIOLOGICAL AND BIOCHEMICAL ANTI-HIV ACTIVITY OF THE BENZOTHIADIAZINE CLASS OF NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS [J].
BUCKHEIT, RW ;
FLIAKASBOLTZ, V ;
DECKER, WD ;
ROBERSON, JL ;
PYLE, CA ;
WHITE, EL ;
BOWDEN, BJ ;
MCMAHON, JB ;
BOYD, MR ;
BADER, JP ;
NICKELL, DG ;
BARTH, H ;
ANTONUCCI, TK .
ANTIVIRAL RESEARCH, 1994, 25 (01) :43-56